Literature DB >> 23606916

Theranostic upconversion nanoparticles (I).

Guanying Chen, Gang Han.   

Abstract

This theme issue provides a comprehensive collection of original research articles on the creation of diverse types of theranostic upconversion nanoparticles, their fundamental interactions in biology, as well as their biophotonic applications in noninvasive diagnostics and therapy.

Entities:  

Keywords:  Bioimaging; Multimodal.; Nontoxicity; Plasmonics; Upconversion

Mesh:

Year:  2013        PMID: 23606916      PMCID: PMC3630530          DOI: 10.7150/thno.6382

Source DB:  PubMed          Journal:  Theranostics        ISSN: 1838-7640            Impact factor:   11.556


Photon upconversion is a non-linear anti-Stokes process that converts two or more low-energy excitation photons, which are generally near infrared (NIR) light, into higher energy shorter wavelength emissions (e.g., NIR, visible, ultraviolet) through the use of long lifetime and real ladder-like energy levels of trivalent lanthanide ions embedded in an appropriate inorganic host lattice 1-4. The recent emerging upconversion nanoparticle has created numerous opportunities for diagnostics and therapy due to the integration of the advantages of its unique dimensions as well as its special unnatural optical properties. These nanoparticles have a multitude of uses toward diagnosis and therapy. For example, (1) the NIR emission can allow for high contrast deep tissue imaging, thus ideal for image-guided surgery through which the tumor located deep inside a body can be seen and treated simultaneously, (2) in biology, ultraviolet emissions are capable of activating photochemical reactions. In addition, their unique optical and chemical properties, such as non-blinking, non-photobleaching, absence of autofluorescence, low-toxicity, and low photodamage to the living system further strengthens their use in medical diagnostics and imaging at both single molecule and ensemble levels. Moreover, a new direction for theranostic upconversion nanoparticles is that of building hierarchical nanostructures for various imaging and therapy applications, such as plasmonics, magnetic resonance imaging (MRI), x-ray computed tomography (CT) and positron emission tomography (PET) for in vitro and in vivo theranostics. This issue (volume 3, number 4) and the next issue (volume 3, number 5) of Theranostics, dedicated to “Theranostic Upconversion Nanoparticles”, are aimed at covering aspects of forefront development of upconversion nanoparticles in theranostics. The research articles in this issue include nanoparticle toxicity, plasmonic interactions, protein and stem-cell imaging, as well as therapy. Wolfbeis et al. developed protein-reactive multicolor upconverison nanoparticles using a poly(ethylene glycol) spacer and N-hydroxysuccinimide ester groups 5. Han et al. produced polyethylenimine (PEI) covalently conjugated core/shell (α-NaYbF4:Tm3+)/CaF2 upconversion nanoparticles for the labeling of rat mesenchymal stem cells (rMSCs). Upon in vitro induction, this exhibited normal osteogenic and adipogenic differentiation 6. Cui et al. implemented a toxicity assessment of water-dispersed LaF3:Yb,Er upconversion nanoparticles in zebrafish 7. This study offers a better understanding for the future study of the toxicological mechanism of these nanoparticles. A core/shell NaYF4:Er3+,Yb3+@SiO2 design by Hilderbrand et al. with highly absorbing NIR carbocyanine dyes in the outer silica shell produced a new tool in terms of combining molecular imaging and photo-thermal therapy 8. Lastly, the interaction of upconversion with plasmonics has been investigated by Lu et al. 9 and Prasad et al. 10 and has displayed impressive plasmonic enhancement of upconversion emissions, as well as optical multimodal imaging capability. All told, this special issue reports on the frontline findings with respect to the theranostic applications of upconversion nanoparticles, which in turn encourages new directions for combined diagnosis and therapy. Despite recent exciting results in developing theranostic upconversion nanoparticles, challenges remain for those working in the field. In this regard, we ask the following two questions: What is the major hurdle in the development of upconversion nanoparticles for biomedical applications? What may be the next big thing in this area? We surveyed some of the leading scientists in the field and the answers vary. So, what is the major hurdle in the development of upconversion nanoparticles for biomedical applications? Professors Chunhua Yan and Ling-Dong Sun from Peking University, as well as our theme contributor Professor Otto S. Wolfbeis from the University of Regensburg, believe that it is the production of upconversion nanoparticles in a highly reproducible way. The reproducibility includes size, size distribution, having a consistent crystal structure, spectral properties and surface modifications. While Professor J. A. Capobianco from Concordia University believes that a detailed understanding of the surface chemistry of nanoparticles is the biggest hurdle. In other words, what is missing here is knowledge is the precise interactions between the surface atoms and functional ligands, as well as the interaction between the resulting surface tailored nanoparticles and molecules (e.g., DNA, proteins) in biological cues. In addition, Professor Wenbo Bu from the Shanghai Institute of Ceramics, the Chinese Academy of Sciences, believes that the largest hurdle in the development of UCNPs for biomedical applications is the active/passive targeting in diagnosis and treatment. On the other hand, Prof. Yong Zhang from the National University of Singapore feels that the biggest hurdle is that the efficiency and emission color cannot satisfy practical applications. What may be the next big thing in this area? Professors Chunhua Yan and Ling-Dong Sun believe that a shift in excitation wavelength from 980 nm to a more appropriate wavelength that produces a much lower heating effect is the next big step in the field. Professor Wenbo Bu believes that the next big thing is the optimization of particle size, surface characteristics, as well as targeting efficiency in vivo. Professor J. A. Capobianco feels that we must carry out more studies on animals or develop an appropriate model. In addition, new upconverting materials must be synthesized to the point that they show more efficient upconversion. Professor Yong Zhang believes that higher efficiency and more emission colors must be created utilizing lanthanide doping and new host materials or new structure. To summarize, this is a quite diverse collection of reviews and research articles that offer us an overview of the study of various upconversion nanoparticles for diagnostic and therapeutic applications. We sincerely hope that the intriguing thoughts and opinions expressed by the contributors to this special issue will provide much of the common ground needed to advance the field of theranostic upconversion nanoparticles.
  10 in total

1.  Upconversion and anti-Stokes processes with f and d ions in solids.

Authors:  François Auzel
Journal:  Chem Rev       Date:  2004-01       Impact factor: 60.622

Review 2.  Upconversion nanophosphors for small-animal imaging.

Authors:  Jing Zhou; Zhuang Liu; Fuyou Li
Journal:  Chem Soc Rev       Date:  2011-10-19       Impact factor: 54.564

3.  Upconverting nanoparticles.

Authors:  Markus Haase; Helmut Schäfer
Journal:  Angew Chem Int Ed Engl       Date:  2011-05-30       Impact factor: 15.336

4.  Nanophotonics and nanochemistry: controlling the excitation dynamics for frequency up- and down-conversion in lanthanide-doped nanoparticles.

Authors:  Guanying Chen; Chunhui Yang; Paras N Prasad
Journal:  Acc Chem Res       Date:  2013-01-22       Impact factor: 22.384

5.  Upconverting organic dye doped core-shell nano-composites for dual-modality NIR imaging and photo-thermal therapy.

Authors:  Guobin Shan; Ralph Weissleder; Scott A Hilderbrand
Journal:  Theranostics       Date:  2013-03-21       Impact factor: 11.556

6.  Distance dependence of gold-enhanced upconversion luminescence in Au/SiO2/Y2O3:Yb3+, Er3+ nanoparticles.

Authors:  W Ge; X R Zhang; M Liu; Z W Lei; R J Knize; Yalin Lu
Journal:  Theranostics       Date:  2013-03-21       Impact factor: 11.556

7.  Toxicity assessments of near-infrared upconversion luminescent LaF3:Yb,Er in early development of zebrafish embryos.

Authors:  Kan Wang; Jiebing Ma; Meng He; Guo Gao; Hao Xu; Jie Sang; Yuxia Wang; Baoquan Zhao; Daxiang Cui
Journal:  Theranostics       Date:  2013-03-20       Impact factor: 11.556

8.  Facile synthesis and potential bioimaging applications of hybrid upconverting and plasmonic NaGdF4: Yb3+, Er3+/silica/gold nanoparticles.

Authors:  Sha Liu; Guanying Chen; Tymish Y Ohulchanskyy; Mark T Swihart; Paras N Prasad
Journal:  Theranostics       Date:  2013-03-21       Impact factor: 11.556

9.  Multicolor upconversion nanoparticles for protein conjugation.

Authors:  Stefan Wilhelm; Thomas Hirsch; Wendy M Patterson; Elisabeth Scheucher; Torsten Mayr; Otto S Wolfbeis
Journal:  Theranostics       Date:  2013-03-13       Impact factor: 11.556

10.  Stem cell labeling using polyethylenimine conjugated (α-NaYbF4:Tm3+)/CaF2 upconversion nanoparticles.

Authors:  Liang Zhao; Artem Kutikov; Jie Shen; Chunying Duan; Jie Song; Gang Han
Journal:  Theranostics       Date:  2013-03-20       Impact factor: 11.556

  10 in total
  3 in total

1.  Dye-Sensitized Core/Active Shell Upconversion Nanoparticles for Optogenetics and Bioimaging Applications.

Authors:  Xiang Wu; Yuanwei Zhang; Kendra Takle; Osman Bilsel; Zhanjun Li; Hyungseok Lee; Zijiao Zhang; Dongsheng Li; Wei Fan; Chunying Duan; Emory M Chan; Carlos Lois; Yang Xiang; Gang Han
Journal:  ACS Nano       Date:  2016-01-11       Impact factor: 15.881

2.  Theranostic upconversion nanoparticles (II).

Authors:  Gang Han; Guanying Chen
Journal:  Theranostics       Date:  2013-04-25       Impact factor: 11.556

3.  Synthesis and functionalization of NaGdF4:Yb,Er@NaGdF4 core-shell nanoparticles for possible application as multimodal contrast agents.

Authors:  Dovile Baziulyte-Paulaviciene; Vitalijus Karabanovas; Marius Stasys; Greta Jarockyte; Vilius Poderys; Simas Sakirzanovas; Ricardas Rotomskis
Journal:  Beilstein J Nanotechnol       Date:  2017-09-01       Impact factor: 3.649

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.